Idexx Laboratories Accounts Receivable increased by 9.3% to $603.54M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 14.4%, from $527.46M to $603.54M. Over 5 years (FY 2020 to FY 2025), Accounts Receivable shows an upward trend with a 10.8% CAGR.
An increase relative to sales may signal slowing collections or credit risk, while a decrease suggests efficient cash conversion.
The total amount of credit extended to customers and channel partners for products sold or services rendered, minus an a...
Typically scales with revenue growth; however, companies with strong direct-to-consumer channels may have lower receivables relative to those relying on third-party distributors.
accounts_receivable_net| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $382.31M | $376.76M | $368.35M | $402.24M | $412.90M | $388.07M | $400.62M | $446.03M | $461.86M | $452.70M | $457.45M | $507.21M | $533.61M | $511.25M | $473.58M | $527.46M | $560.56M | $566.88M | $552.38M | $603.54M |
| QoQ Change | — | -1.5% | -2.2% | +9.2% | +2.7% | -6.0% | +3.2% | +11.3% | +3.5% | -2.0% | +1.0% | +10.9% | +5.2% | -4.2% | -7.4% | +11.4% | +6.3% | +1.1% | -2.6% | +9.3% |
| YoY Change | — | — | — | — | +8.0% | +3.0% | +8.8% | +10.9% | +11.9% | +16.7% | +14.2% | +13.7% | +15.5% | +12.9% | +3.5% | +4.0% | +5.1% | +10.9% | +16.6% | +14.4% |